They lose 24 kg thanks to the weight loss drug “Tirzepatide”


Eli Lilly and Company, an American laboratory, has just developed a drug capable of making obese patients lose weight in record time. This drug is none other than the Tirzepatide.

“Tirzepatide caused greater reductions in body weight compared to the initial values after 40 weeks of treatment in adults with type 2 diabetes, according to the first results of the SURPASS-1 clinical trial”, announces the laboratory via a press release.

It would have allowed obese patients to lose up to 22.5% of their body weight.

Tirzepatide releases the hormones that the body releases after a meal

Tirzepatide combines synthetic imitations of two hormones that the body naturally releases following a meal. These hormones, known as GLP-1 and GIP provide that feeling of fullness that you feel after eating. Concretely: if you take this medicine, it should give you the same feeling as when you leave the table.

More than 2,500 people from nine countries took part in the trial. Participants weighed approximately 105 kg. Each week, participants were given low, medium, or high doses of the drug. Some of the participants took a placebo.

Participants were not told whether they were taking a low, high, medium dose, or a placebo. People who consumed the highest dose of the drug have lost 24 kg.

Participants who took lower doses also saw improvements in their weight. Scientists point out, however, that as is the case with any other weight-loss drug, for it to bear fruit, it must be accompanied by a healthy lifestyle in parallel.

Tirzepatide: “remarkable results never obtained before”

Tirzepatide is not the first drug to be talked about for its weight loss abilities. Another drug, known as Semaglutide had shown results and was approved by the FDA (Food and Drug Administration). The latter, however, involved side effects, such as nausea and diarrhoea.

The Tirzepatide, however, seems surpass Semaglutide.

“These phase III data for Tirzepatide are promising and build on phase II data published in 2018. exceptional reductions in HbA1c and body weight in people with type 2 diabetes, says Sue Pedersen, an endocrinologist and researcher conducting clinical trials in diabetes and obesity at the C-ENDO Diabetes & Endocrinology Clinic in Calgary, Alta. This is a remarkable result that we never got before with hypoglycemics.

Leave A Reply

Your email address will not be published.